UroGen Pharma Ltd.

NASDAQ:URGN

Biotechnology

Healthcare
$29.79 -1.22%

-$0.40 today

Market cap
$1.46B
Beta
1.62
P/E (TTM)
-12.2
EPS (TTM)
-$2.65
52W Low $12.73High $33.79

Volume 1.14M

Average 0.79M

URGN Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

UroGen Pharma Ltd.NASDAQ: URGN

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of $4.14M rose 77.6% year over year, ahead of the +50.3% change in trailing-twelve-month cost of revenue. Sequentially, it rose 25.8% from the prior quarter. Over 3 fiscal years it compounded at +17.6% a year.

Context

  • Cost of revenue amounted to 11.3% of revenue in FY2025, up 1.5 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +77.6% holds above the trailing-twelve-month pace of +50.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.14M+25.8% QoQ
Last fiscal yearDec 2025
$12.45M+40.2% YoY
LTMMar 2026
$14.26M+50.3% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+77.6%——
1 year+40.2%——
3-year CAGR+17.6%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
12.45M USD
Year-over-year change
+40.2%
4-year CAGR
+24.6%

Cost of Revenue vs competitors

How URGN compares with its peers on the latest reported figures

  • URGN's LTM Mar 2026 cost of revenue of $14.26M is the highest of the 3 companies compared; the peer median is $6.24M.
  • Its year-over-year change of +50.3% is the highest of 2, against a peer median of -85.7%.
  • Cost of revenue amounts to 10.1% of revenue for URGN, versus a peer median of 202.2%.
URGN Competitors Peer median
Cost of Revenue for URGN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
URGNUroGen Pharma Ltd.LTM Mar 2026$14.26M +50.3%+17.6%10.1%
CGONCG Oncology, Inc. Common stockLTM Sep 2026$12.47M -85.7%+576.6%202.2%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 ———
Peer median (excluding URGN) $6.24M-85.7%+576.6%202.2%

Competitors are the stored peer set for URGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.04M64.36M82.71M90.4M109.79M
Cost of Revenue5.16M7.65M9.36M8.88M12.45M
Gross Profit42.89M56.7M73.35M81.52M97.34M
Gross Margin89.3%88.1%88.7%90.2%88.7%
Research & Development47.64M52.91M45.61M57.15M67.11M
Selling, General & Admin082.84M93.27M0155.1M
Operating Expenses135.18M135.74M138.89M178.3M222.2M
Depreciation & Amortization831K1.82M1.71M329K2.41M
EBITDA(108.54M)(76.21M)(60.35M)(95.35M)(135.66M)
EBITDA Margin-225.9%-118.4%-73.0%-105.5%-123.6%
Operating Income(92.29M)(79.04M)(65.54M)(96.78M)(124.86M)
Operating Margin-192.1%-122.8%-79.2%-107.1%-113.7%
Interest Income365K938K2.64M8.9M5.97M
Interest Expense17.44M8.44M14.72M12.52M33.85M
Other Income / Expenses(17.08M)(28.99M)(32.79M)(27.26M)(28.55M)
Income Before Tax(109.37M)(108.03M)(98.32M)(124.04M)(153.42M)
Pre-Tax Margin-227.7%-167.9%-118.9%-137.2%-139.7%
Income Tax Expense1.45M1.76M3.92M2.83M78K
Net Income(110.82M)(109.78M)(102.24M)(126.87M)(153.49M)
Net Margin-230.7%-170.6%-123.6%-140.4%-139.8%
EPS (Basic)(4.96)(4.79)(3.55)(2.96)(3.19)
EPS (Diluted)(4.96)(4.79)(3.55)(2.96)(3.19)
Weighted Avg Shares22.35M22.81M28.83M42.88M48.12M
Weighted Avg Shares (Diluted)22.35M22.81M28.83M42.88M48.12M

UroGen Pharma Ltd.

NASDAQ:URGN

Intrinsic Alpha fair value

Locked

Current Price

$29.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.